Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

NCT06924710 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

286

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Standard Therapy
OTHER: Adaptive Therapy

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]